IP Library Granted Patent US 8,318,162
Granted Patent B2
US 8,318,162 · App. 13/384,197 · Granted Nov 27, 2012

Antibodies to high molecular weight melanoma associated antigen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,162
App. No.
13/384,197
Granted
Nov 27, 2012
Kind
B2
Abstract

The present disclosure relates to anti-high molecular weight melanoma associated antigen (HMW-MAA) antibodies which bind to human HMW-MAA. Such antibodies may be used to treat diseases or disorders characterized by expression of HMW-MAA including cancer, for example, melanoma, basal cell carcinoma, ALL or AML.

Claims (10)

1. An isolated anti-high molecular weight melanoma associated antigen (HMW-MAA) antibody (anti-HMW-MAA) or antigen binding fragment thereof which binds to human HMW-MAA comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO 12.

2. A conjugate comprising the anti-HMW-MAA antibody or antigen binding fragment thereof of claim 1 bound to a cytotoxic or non-cytotoxic agent.

3. A method for determining the presence of HMW-MAA protein comprising exposing a sample suspected of containing the HMW-MAA protein to the anti-HMW-MAA antibody or antigen binding fragment thereof of claim 1 and detecting binding of the antibody or antigen binding fragment thereof to the sample, wherein the binding of the antibody or antigen binding fragment thereof to the sample is indicative of the presence of HMW-MAA protein in the sample.

4. A kit comprising the anti-HMW-MAA antibody or antigen binding fragment thereof of claim 1 and instructions for using the anti-HMW-MAA antibody or antigen binding fragment thereof to detect the HMW-MAA protein.

5. A composition comprising one or more anti-HMW-MAA antibodies or antigen binding fragments thereof of claim 1 and one or more pharmaceutically acceptable carriers or diluents.

6. The anti-HMW-MAA antibody of claim 1 , wherein the antibody is a full length antibody.

7. The anti-HMW-MAA antibody of claim 1 , wherein the antibody is a human IgG.

8. The anti-HMW-MAA antibody or antigen binding fragment thereof of claim 1 , wherein the antigen binding fragment is a Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 or SCA (single chain antibody).

9. A conjugated anti-HMW-MAA antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is bound to a detectable label.

10. An immobilized anti-HMW-MAA antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is bound to a solid phase.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2025
From: SILICON VALLEY BANK
To: XOMA TECHNOLOGY LTD.
Reel/Frame 073790/0484 →
SECURITY INTEREST Recorded May 9, 2018
From: XOMA TECHNOLOGY LTD.
To: SILICON VALLEY BANK
Reel/Frame 046115/0459 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2012
From: HORWITZ, ARNOLD H
To: XOMA TECHNOLOGY LTD.
Reel/Frame 027774/0476 →